OMEROS CORP
USUSDOMEROS CORP (US:OMER) — Biotechnology: Pharmaceutical Preparations. Nombre de places boursières sur lesquelles les actions de la société sont cotées : 2. Sur cette page : cours et graphique, dividendes, principaux actionnaires et historique du nombre d'actions.
À propos de l'entreprise
- Site web
- omeros.com
- Secteur
- Health Care · Biotechnology: Pharmaceutical Preparations
- Siège social
- SEATTLE, United States
- PDG
- Gregory A. Demopulos
- Employés
- 175
- Actions en circulation
- 72.39 M au 2026-08-07
- Flottant
- 69.29 M
- Capitalisation boursière
- 1.44 Md USD
- Initiés
- 4.08%
- Investisseurs institutionnels
- 51.42%
- Secteur d'activité (SIC)
- Pharmaceutical Preparations
- FCF
- −68.7 M USD
- Dette
- 87.9 M USD
- Résultats et FCF — pour les 12 mois à 30.06.2026 (dernier rapport de l'entreprise).
Description
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome. It also develops OMS1029 that has completed phase I clinical trials for mannan-binding lectin-associated serine protease 2 (MASP-2) and lectin pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders, as well as cocaine use disorder. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; OncotoX-AML, to treat acute myeloid leukemia; and Targeted Complement Activating Therapy, for Multidrug-resistant organisms. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.
Actualités de cette semaine
Pas encore d'actualités du site de l'entreprise.
Principaux actionnaires
| Détenteur | Participation | Actions | Date du rapport |
|---|---|---|---|
| Blackrock Inc. | 8.35% | 6.04 M | 2026-06-30 |
| Ingalls & Snyder LLC | 5.06% | 3.66 M | 2026-06-30 |
| UBS Group AG | 4.35% | 3.15 M | 2026-06-30 |
| Vanguard Capital Managem… | 4.24% | 3.07 M | 2026-06-30 |
| State Street Corporation | 3.2% | 2.32 M | 2026-06-30 |
| DEMOPULOS GREGORY A. M.D… | ≈3.03% | 2.19 M | 2026-02-18 |
| VANGUARD INDEX FUNDS-Van… | 3% | 2.17 M | 2026-06-30 |
| Geode Capital Management… | 2.64% | 1.91 M | 2026-06-30 |
| iShares Trust-iShares Ru… | 2.55% | 1.85 M | 2026-08-31 |
| Stifel Financial Corpora… | 2.54% | 1.84 M | 2026-06-30 |
| Vanguard Portfolio Manag… | 1.33% | 962 828 | 2026-06-30 |
| Invesco Exchange-Traded… | 1.28% | 929 585 | 2026-08-31 |
| SPDR SERIES TRUST-State… | 1.21% | 873 173 | 2026-08-31 |
| VANGUARD INDEX FUNDS-Van… | 1.15% | 831 218 | 2026-06-30 |
| Fidelity Salem Street Tr… | 1.09% | 788 562 | 2026-07-31 |
| Invesco Ltd. | 1.04% | 751 771 | 2026-06-30 |
| Northern Trust Corporati… | 1% | 727 348 | 2026-06-30 |
| iShares Trust-iShares Ru… | 0.58% | 421 600 | 2026-08-31 |
| Fidelity Concord Street… | 0.49% | 357 371 | 2026-07-31 |
| VANGUARD SCOTTSDALE FUND… | 0.49% | 352 679 | 2026-05-31 |
| SCHWAB STRATEGIC TRUST-S… | 0.47% | 343 807 | 2026-05-31 |
| CABLE THOMAS J (Director… | ≈0.05% | 35 067 | 2026-08-20 |
| HANISH ARNOLD C (Directo… | ≈0.02% | 12 400 | 2026-08-27 |
| CANCELMO PETER B. (Gener… | ≈0% | 200 | 2026-08-31 |
| BORGES DAVID J. (Officer… | — | 0 | 2026-09-23 |
